1r2e: Difference between revisions
New page: left|200px<br /> <applet load="1r2e" size="450" color="white" frame="true" align="right" spinBox="true" caption="1r2e, resolution 2.10Å" /> '''Human Bcl-XL contai... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1r2e.gif|left|200px]]<br /> | [[Image:1r2e.gif|left|200px]]<br /><applet load="1r2e" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1r2e" size=" | |||
caption="1r2e, resolution 2.10Å" /> | caption="1r2e, resolution 2.10Å" /> | ||
'''Human Bcl-XL containing a Glu to Leu mutation at position 92'''<br /> | '''Human Bcl-XL containing a Glu to Leu mutation at position 92'''<br /> | ||
==Overview== | ==Overview== | ||
Cells expressing high levels of the BCL-X(L) anti-apoptotic protein are | Cells expressing high levels of the BCL-X(L) anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A (AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-X(L), previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-X(L) hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD(50) of AA for cells expressing BCL-X(L) mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-X(L) is a principal target mediating AA cytotoxicity. | ||
==About this Structure== | ==About this Structure== | ||
1R2E is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http:// | 1R2E is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1R2E OCA]. | ||
==Reference== | ==Reference== | ||
| Line 14: | Line 13: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Giedt, C | [[Category: Giedt, C D.]] | ||
[[Category: Hockenbery, D | [[Category: Hockenbery, D M.]] | ||
[[Category: Kim, K | [[Category: Kim, K M.]] | ||
[[Category: Manion, M | [[Category: Manion, M K.]] | ||
[[Category: Neill, J | [[Category: Neill, J W.O.]] | ||
[[Category: Zhang, K | [[Category: Zhang, K Y.]] | ||
[[Category: alpha-helical]] | [[Category: alpha-helical]] | ||
[[Category: apoptosis]] | [[Category: apoptosis]] | ||
| Line 25: | Line 24: | ||
[[Category: mutation]] | [[Category: mutation]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:46:16 2008'' | ||
Revision as of 12:46, 21 February 2008
|
Human Bcl-XL containing a Glu to Leu mutation at position 92
Overview
Cells expressing high levels of the BCL-X(L) anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A (AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-X(L), previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-X(L) hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD(50) of AA for cells expressing BCL-X(L) mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-X(L) is a principal target mediating AA cytotoxicity.
About this Structure
1R2E is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Bcl-XL mutations suppress cellular sensitivity to antimycin A., Manion MK, O'Neill JW, Giedt CD, Kim KM, Zhang KY, Hockenbery DM, J Biol Chem. 2004 Jan 16;279(3):2159-65. Epub 2003 Oct 8. PMID:14534311
Page seeded by OCA on Thu Feb 21 14:46:16 2008
